Van Zyl, J. A.Van Der Walt, J. J.Van Zyl, J. J. W.(Health and Medical Publishing Group (HMPG), 1975)
In this case of angiosarcoma of the breast in a 55 yr old woman, the time from treatment to death was 41 mth, compared with 25 mth in collected cases from the literature. The possible value of adjuvant chemotherapy is ...
Apffelstaedt, J. P.Steenkamp, V.Baatjes, K.(Health and Medical Publishing Group (HMPG), 2008)
Background. Mammographic screening has become part of routine health care. We present a first analysis of screening mammography in a dedicated breast health centre in Africa. Objective. To establish a performance benchmark ...
Sidler, D.Arndt, H. R.Van Niekerk, A. A.(Health and Medical Publishing Group (HMPG), 2008-04)
Acceptance of the concept of medical futility facilitates a paradigm shift from curative to palliative medicine, accommodating a more humane approach and avoiding unnecessary suffering in the course of the dying process. ...
Klitgaard, ThomasTabanera y Palacios, ReneBoffard, KennethLau, Philip T. C.Warren, BrianRizoli, SandroRossaint, RolfKluger, YoramRiou, Bruno(BioMed Central, 2006-07)
Introduction: Recombinant activated factor VII (rFVIIa) has been used as adjunctive therapy in trauma patients with severe bleeding. However, its pharmacokinetics profile remains unknown. Methods: In two placebo-controlled ...
Introduction: We conducted a post-hoc analysis on the effect of recombinant factor VIIa (rFVIIa) on coagulopathic patients from two randomized, placebo-controlled, double-blind trials of rFVIIa as an adjunctive therapy for ...
Kluger, YoramRiou, BrunoRossaint, RolfRizoli, Sandro B.Boffard, Kenneth D.Choong, Philip Iau TsauWarren, BrianTillinger, Michael(BioMed Central, 2007-08)
Background: Trauma is a leading cause of mortality and morbidity, with traumatic brain injury (TBI) and uncontrolled hemorrhage responsible for the majority of these deaths. Recombinant activated factor VIIa (rFVIIa) is ...